MicroQuin Secures DoD CDMRP Grant to Advance Ovarian Cancer Treatment Innovations

Ovarian cancer remains one of the most challenging cancers to treat, with survival rates lagging behind many other cancers. Recent news brings hope as MicroQuin, a biotechnology company, has been awarded a grant from the Department of Defense’s Congressionally Directed Medical Research Programs (DoD CDMRP). This funding will support the development of new treatment options for ovarian cancer, aiming to improve outcomes for patients facing this disease.

MicroQuin laboratory equipment for ovarian cancer research